Clinical Study to Determine Bioequivalence of Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Male Subjects Under Fasted Conditions

The study design was a randomized, open-label, two-way, crossover, single-dose, prospective, and longitudinal study, with a 7-day wash-out period before next dosing; to compare the pharmacokinetic profile (Cmax, AUC0-t and AUC0-inf) of two 0.4 mg tamsulosin extended release tablet in thirty-four (34) healthy male Mexican adult volunteers aged 18 to 55 years.

Inclusion criteria

• Age between 18 and 55 years.
• Clinically healthy male according to the updated medical history prior to the start of the study.
• Not blocked in the COFEPRIS research subject database.
• Body mass index between 18 and 27 kg/m².
• Normal vital signs: Heart rate between 60 and 99 beats per minute, respiratory rate between 12 and 20 breaths per minute, systolic blood pressure between 90-130 mmHg, diastolic blood pressure between 60-89 mmHg, and temperature between 36.0 and 37.4°C.
• Electrocardiogram (ECG) without any signs of pathology.
• Clinical laboratory test results within normal limits or with clinically insignificant variations.
• Negative biosafety tests for the presence of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and varicella-zoster virus (VDRL).
• Negative drug screening tests for amphetamines, benzodiazepines, cocaine, methamphetamines, morphine, and tetrahydrocannabinol (THC).
• Negative breath alcohol test.
• Research subjects with no history of alcohol abuse or dependence, psychoactive substance abuse, or chronic medication use.
• Subjects with a signed informed consent form.

Exclusion criteria

• Subjects with a history of hypersensitivity to the study drug.
• Subjects with lactose intolerance.
• Subjects with a history of cardiovascular, renal, hepatic, metabolic, gastrointestinal, neurological, endocrine, hematopoietic (any type of anemia), mental illness, or other organic abnormalities that could affect the pharmacokinetic study of the study product.
• Subjects requiring any medication during the course of the study that interferes with the quantification or pharmacokinetics of the study drug.
• Subjects who have been exposed to agents known to induce or inhibit hepatic enzyme systems or who have taken potentially toxic medications within 30 days prior to the start of the study.
• Subjects who, prior to receiving the study drug, have taken medications such as those described in section 3.11 "Drug Interactions."
• Subjects who have been hospitalized for any reason within sixty days prior to the start of the study or who have been seriously ill within thirty days prior to the start of the study.
• Subjects who have received an investigational drug within ninety days prior to the start of the study.
• Subjects who have donated or lost 450 mL or more of blood within sixty days prior to the start of the study.
• Research subjects with a history of alcohol or psychoactive substance abuse or dependence, or chronic medication use.
• Subjects who have consumed beverages or foods containing xanthines (coffee, tea, cocoa, chocolate, yerba mate, cola, etc.) or have consumed charcoal-grilled foods within 12 hours prior to administration of the medication dose.
• Subjects who have consumed grapefruit, cranberry, or pomegranate juice within 12 hours prior to the study.
• Subjects who have smoked at least 12 hours before the start of the study.
• Subjects who have ingested alcoholic beverages 48 hours prior to administration of the dose.